Fluticasone propionate inhalation - Teva Pharmaceutical Industries

Drug Profile

Fluticasone propionate inhalation - Teva Pharmaceutical Industries

Alternative Names: Fluticasone propionate MDPI; Fluticasone propionate MDPI - Teva Pharmaceutical Industries; Fluticasone propionate RespiClick®

Latest Information Update: 05 Dec 2016

Price : $50

At a glance

  • Originator Teva Pharmaceutical Industries
  • Class Androstadienes; Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Asthma

Most Recent Events

  • 30 Nov 2016 Teva Branded Pharmaceutical Products, R&D plans a phase III trial for Asthma (In children) in USA (Inhalation) (NCT02980133)
  • 01 Aug 2016 Teva completes a phase I pharmacokinetic trial for Asthma (In children) in USA (NCT02680561)
  • 28 Jun 2016 Final adverse events data from the phase III trials in Asthma (In adolescents, In children) released by Teva Pharmaceutical Industries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top